Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases*

Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases*

Autor Callegaro-Filho, D. Autor UNIFESP Google Scholar
Gershenson, D. M. Google Scholar
Nick, A. M. Google Scholar
Munsell, M. F. Google Scholar
Ramirez, P. T. Google Scholar
Eifel, P. J. Google Scholar
Euscher, E. D. Google Scholar
Marques, R. M. Autor UNIFESP Google Scholar
Nicolau, S. M. Autor UNIFESP Google Scholar
Schmeler, K. M. Google Scholar
Resumo Objective. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare disease with a poor prognosis. SCCOHT has recently been shown to be associated with SMARCA4 gene mutations as well as molecular and genetic similarities to malignant rhabdoid tumors (MRT). The objective of our study is to describe the clinical characteristics, treatment modalities and outcomes of 47 patients with SCCOHT. Methods. We performed a retrospective analysis of 47 patients with SCCOHT evaluated at MD Anderson Cancer Center between 1990 and 2014. Medical records were reviewed for demographic information, pathologic findings, treatment regimens and outcomes. Results. Median age at diagnosis was 30 years (range 5-46). All patients underwent surgery with unilateral salpingo-oophorectomy (USO) performed in 26 patients (55%), and hysterectomy with bilateral salping000phorectomy (BSO) in 21 patients (45%). Sixteen patients (34.0%) had stage I disease, six (12.8%) stage II, 23 (48.9%) stage III, and two patients (4.3%) had stage IV disease. Information on adjuvant treatment was available for 43 patients: 83.3% received chemotherapy alone, 9.5% chemotherapy followed by radiotherapy, 2.4% chemoradiation, and 4.8% did not receive any adjuvant therapy. Median follow-up was 13.2 months (range, 0.1 to 210.7) with a median overall survival of 14.9 months. Multi-agent chemotherapy and radiotherapy were associated with a better prognosis. Conclusion. Our findings suggest that aggressive therapy including multi-agent chemotherapy and possibly radiotherapy may extend survival. Further study is needed to improve outcomes in these patients including the adoption of systemic therapies used in MRT as well as the development of novel agents targeting specific mutations. (c) 2015 Elsevier Inc. All rights reserved.
Assunto Small cell carcinoma of the ovary
Hypercalcemic type
VPCBAE
Radiotherapy
SMARCA4
Malignant rhabdoid tumorRhabdoid Tumor
Smarca4 Mutations
Chemotherapy
Experience
Management
Kidney
Idioma Inglês
Financiador National Institutes of Health through MD Anderson's Cancer Center Support Grant [CA016672]
Número do financiamento National Institutes of Health through MD Anderson's Cancer Center Support Grant CA016672.
Data 2016
Publicado em Gynecologic Oncology. San Diego, v. 140, n. 1, p. 53-57, 2016.
ISSN 0090-8258 (Sherpa/Romeo, fator de impacto)
Editor Academic Press Inc Elsevier Science
Extensão 53-57
Fonte http://dx.doi.org/10.1016/j.ygyno.2015.11.004
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000367869100011
URI http://repositorio.unifesp.br/handle/11600/46064

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)